1. Home
  2. Companies
  3. ALA
  4. Material Events

Arovella Therapeutics (ASX:ALA) — Material Events

ASX:ALA · 14 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 13 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
Arovella’s CLDN18.2 CAR-T Cells Show Potent Pancreatic Cancer Killing, Next Step, CAR-iNKT TherapyMedium
Arovella's CLDN18.2 CAR-T cells show potent pancreatic cancer cell killing; advancing CAR-iNKT therapy development
2 Oct 2025 ·ASX Release ·85
Arovella Advances CAR-iNKT Trials with $14.4 Million Cash BackingMedium
Arovella advances CAR-iNKT clinical trials and solid tumour program with strong cash position
27 July 2026 ·Quarterly Activities and Cash Flow Report ·85
Arovella Advances with First Clinical Batch of ALA-101 and Trial Site ActivationMedium
Arovella releases first clinical batch of ALA-101 and activates first trial site
7 Sept 2026 ·Clinical Trial Update ·85
Arovella Advances with IND Filing for Pioneering CAR-iNKT TherapyMedium
Arovella submits IND to FDA for Phase 1 trial of ALA-101 CAR-iNKT cell therapy
30 Dec 2025 ·Regulatory Filing ·85
FDA Greenlights Arovella’s ALA-101 for First Human Trials in Blood CancersHigh
FDA Accepts IND for Arovella’s ALA-101, Paving Way for First Human Trials
29 Jan 2026 ·Regulatory Announcement ·85
Arovella Advances Toward Clinical Trials with Positive FDA Feedback on CAR-iNKT TherapyMedium
Arovella Therapeutics receives positive FDA feedback, plans IND filing for ALA-101 in Q4 2025
28 Oct 2025 ·Regulatory Update ·85
Arovella’s CLDN18.2 CAR-iNKT Cells Show Durable Killing of Pancreatic and Gastric CancerMedium
Arovella’s CLDN18.2 CAR-iNKT Cells with IL-12-TM Show Potent Killing of Pancreatic and Gastric Cancer Cells
1 Apr 2026 ·ASX Release ·85
Arovella Advances CAR-iNKT Therapy with IND Filing and $19.4M Cash BackingHigh
Arovella files IND for ALA-101, advances CAR-iNKT pipeline, appoints new director, and reports $19.4M cash
23 Jan 2026 ·Appendix 4C Quarterly Cash Flow and Activity Report ·85
Arovella Advances ALA-101 Toward First Human Trial with $21.9M Cash BufferMedium
Arovella advances ALA-101 IND, secures US patent, prepares phase 1 trial with $21.9M cash
30 Oct 2025 ·Appendix 4C Quarterly Cash Flow and Activity Report ·85
Arovella Accelerates ALA-101 Trial with TGA’s Streamlined ApprovalMedium
Arovella’s ALA-101 Phase 1 Trial Approved by TGA via Streamlined CTN Pathway
16 Mar 2026 ·ASX Release ·80
Arovella Therapeutics Faces Leadership Shake-Up Amid Strategic ReviewMedium
Arovella Therapeutics announces CEO resignation and board refresh amid strategic review
4 May 2026 ·Board and Executive Change Announcement ·Unexpected ·75
Arovella Advances ALA-101 with FDA IND Nod Amid Rising Half-Year LossMedium
Arovella reports $1.88M half-year loss, FDA IND acceptance for lead asset ALA-101, advances CAR-iNKT solid tumor program
19 Feb 2026 ·Appendix 4D Half-year report ·75
Arovella Secures $3.21M R&D Rebate to Propel ALA-101 TrialsMedium
Arovella secures $3.21M R&D tax rebate to fund ALA-101 clinical trials
23 Sept 2025 ·ASX Release ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.